Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 49
Med. infant ; 30(3): 263-269, Septiembre 2023. tab
Article in Spanish | LILACS, UNISALUD, BINACIS | ID: biblio-1515961


Los estudios sobre la infección fúngica invasiva (IFI) por Mucor spp. en pacientes pediátricos con patología hematooncológica, son de baja solidez científica, lo que dificulta conocer en profundidad sus características y evolución. Con el objetivo de analizar la evolución fatal de esos pacientes, se llevó a cabo esta revisión sistemática (RS). Material y métodos: La búsqueda bibliográfica se realizó con fecha 23 de marzo de 2023, en las principales bases de datos (Medline (a través de Pubmed), Embase (a través de Embase-Elsevier), The Cochrane Library (a través de Wiley), Cinahl (a través de Ebsco HOST), SCI-EXPANDED, SciELO (a través de la WOS) y Scopus (a través de Scopus-Elsevier), libre (mediante el motor Google) y revisando las citas de los artículos incluidos. Resultados: Se rescataron 1393 artículos, de los cuales se descartaron 1386 por diversas razones. Mediante el análisis de los textos completos, finalmente se incluyeron 7 estudios. Todos los estudios eran series de casos (nivel 4). La mediana de la frecuencia de muerte observada fue de 36,6% (Q1 20% - Q347%). Conclusiones: Esta RS mostró en niños con patología hemato-oncológica, que la mortalidad por IFI por Mucor spp. alcanzó a casi un tercio de los pacientes (AU)

Studies on invasive fungal infection (IFI) by Mucor spp. in pediatric patients with cancer have a low level of evidence, which makes it difficult to elucidate its characteristics and progression. To analyze the fatal outcome of these patients, this systematic review (SR) was conducted. Material and methods: A literature search was carried out on March 23, 2023, in the following main databases (Medline (via Pubmed), Embase (via Embase-Elsevier), The Cochrane Library (via Wiley), Cinahl (via Ebsco HOST), SCI-EXPANDED, SciELO (via the WOS) and Scopus (via Scopus-Elsevier). Additionally, a complementary search was carried out using free search engines (such as Google) and by reviewing the references of the included articles. Results: A total of 1393 articles were retrieved, of which 1386 were excluded for various reasons. After a thorough analysis of the full-text articles, 7 studies were ultimately included in the review. All studies were case series (level 4). The median observed death rate was 36.6% (IQR, 20% - 47%). Conclusions: This SR showed that in children with hematological-oncological disease, mortality due to IFI by Mucor spp. affected almost one third of the patients (AU)

Humans , Child , Adolescent , Opportunistic Infections/microbiology , Hematologic Neoplasms/complications , Hematologic Neoplasms/mortality , Hematologic Neoplasms/therapy , Invasive Fungal Infections/drug therapy , Mucormycosis/diagnosis , Mucormycosis/drug therapy , Antifungal Agents/therapeutic use , Risk Factors , Immunocompromised Host , Mucor , Neutropenia
Journal of Experimental Hematology ; (6): 389-395, 2023.
Article in Chinese | WPRIM | ID: wpr-982071


OBJECTIVE@#To explore the risk and location of multiple malignancies in patients with hematologic malignancies who were followed up for 9 years in Jiangsu Province Hospital and to evaluate the impact of the second primary malignancy on survival of patients.@*METHODS@#The incidence and survival of multiple malignancies in 7 921 patients with hematologic malignancies from 2009 to 2017 were analyzed retrospectively.@*RESULTS@#A total of 180 (2.3%, 180/7 921) patients developed second malignancy, of whom 58 patients were diagnosed with hematologic malignancies as the first primary malignancy, and 98 patients developed hematologic malignancies as second primary malignancy, and the other 24 cases were diagnosed with the second malignancy within 6 months after the first primary malignancy was diagnosed, which was difined as multiple malignancies occurring simultaneously. In 180 patients, 18 cases developed two hematologic malignancies successively, and 11 patients developed more than 3 primary cancers (among them, 2 female patients were diagnosed with 4 primary cancers). Patients with lymphoma and multiple myeloma (MM) as the second primary malignancy had poorer survival than patients with lymphoma and MM as the first primary malignancy. Patients with chronic myeloid leukemia as the second primary malignancy were also associated with inferior overall survival.@*CONCLUSION@#In this study, 2.3% of hematologic malignancy patients had multiple mali-gnancies, lymphoma and MM as the second primary malignancy had poor survival.

Humans , East Asian People , Hematologic Neoplasms/complications , Lymphoma/complications , Multiple Myeloma/complications , Neoplasms, Second Primary , Retrospective Studies , Survival Analysis
Chinese Journal of Contemporary Pediatrics ; (12): 718-725, 2023.
Article in Chinese | WPRIM | ID: wpr-982018


OBJECTIVES@#To explore the value of metagenomic next-generation sequencing (mNGS) in the pathogen identification in children with hematological malignancies complicated with infections.@*METHODS@#A retrospective analysis was conducted on clinical data and pathogenic test results of 43 children with hematological malignancies who underwent microbial culture and mNGS due to infections in the Third Xiangya Hospital of Central South University between June 2020 and July 2022. Differences in detection rates and characteristics of pathogenic microorganisms detected by mNGS and microbial culture were compared.@*RESULTS@#A total of 54 specimens were examined, and the overall detection rate of pathogen by mNGS (80%, 43/54) was significantly higher than that by microbial culture (30%, 16/54) (P<0.001). The most commonly detected infection type by mNGS was viral infection, followed by fungal infection combined viral infection, while that by microbial culture was bacterial infection, followed by fungal infection. The detection rate of fungi by mNGS (33%, 18/54) was higher than that by microbial culture (6%, 3/54) (P<0.001). The detection rate of two or more pathogenic microorganisms by mNGS was higher at 48% compared to microbial culture at 9% (P<0.05). The detection rate of two or more types of pathogenic microorganisms by mNGS was also significantly higher at 33% compared to microbial culture at 2% (P<0.05). The most commonly detected bacteria and fungi by mNGS were Pseudomonas aeruginosa and Candida tropicalis, respectively, in peripheral blood, while Streptococcus pneumoniae and Pneumocystis jirovecii were most commonly detected in bronchoalveolar lavage fluid. Treatment adjustments based on mNGS results were beneficial for 35% (15/43) of the cases.@*CONCLUSIONS@#mNGS has a higher detection rate than microbial culture and has obvious advantages in diagnosing mixed and fungal infections, making it a useful supplementary diagnostic method to microbial culture.

Humans , Child , Retrospective Studies , Hematologic Neoplasms/complications , High-Throughput Nucleotide Sequencing , Bronchoalveolar Lavage Fluid , Hospitals , Sensitivity and Specificity
Journal of Experimental Hematology ; (6): 924-929, 2022.
Article in Chinese | WPRIM | ID: wpr-939711


OBJECTIVE@#To investigate the clinical characteristics and prognosis of hematological malignancies superimposed patients with solid tumors.@*METHODS@#The clinical data of 30 patients with more than two kinds of malignancy (the second is hematological malignancy) from October 2011 to October 2020 in Department of Hematology, Jiangning Hospital Affiliated to Nanjing Medical University were collected and analyzed retrospectively. The overall survival time was used as the prognostic evaluation standard, and the survival of patients were analyzed by KaplanMeier method. Logrank test and Cox regression model were used to carry out univariate and multivariate retrospective analysis on clinical and laboratory parameters of 30 patients.@*RESULTS@#Among 30 cases, 20 were male, 10 were female, the median age of onset of the second tumor was 70 years old. The common types of the secondary hematological malignancies to solid tumors are myelodysplastic syndrome, acute myeloid leukemia, multiple myeloma. Univariate analysis showed that patients' gender, age, type of solid tumors, the onset of interval between two kinds of tumor, chromosome karyotype were not related to do with the patients' overall survival time. Type of hematologic disease, ECOG score were associated with patients' overall survival time, and the multivariate analysis showed that the type of hematologic disease and ECOG score were independent risk factors for patients with poor prognosis.@*CONCLUSION@#Patients superimposed with solid tumors complicated with myelodysplastic syndrome or acute leukemia and ECOG score ≥3 have poor prognosis and shorter overall survival time, which are independent risk factors influencing the prognosis. Bone marrow injury, immune dysfunction and genetic susceptibility after chemoradiotherapy may be the main causes of these diseases.

Aged , Female , Humans , Male , Hematologic Neoplasms/complications , Leukemia, Myeloid, Acute/complications , Myelodysplastic Syndromes/complications , Prognosis , Retrospective Studies
Medicina (B.Aires) ; 81(3): 396-400, jun. 2021. graf
Article in Spanish | LILACS | ID: biblio-1346475


Resumen La infección por SARS-CoV-2 en pacientes con neoplasias hematológicas y trasplantes de células progenitoras hematopoyéticas (TCPH) puede ser grave y con importante mortalidad. Llevamos a cabo un estudio prospectivo y observacional que tuvo como objetivo describir las características clínicas, epide miológicas y la evolución de la infección por SARS-CoV-2 en pacientes con neoplasias hematológicas y TCPH. Se incluyeron 20 pacientes adultos con una mediana de edad de 58 años y una mediana de score de Charlson de 3. Las infecciones fueron de adquisición comunitaria y nosocomial en el 60% y 40% respectivamente, y el 30% de los pacientes tenía antecedente de contacto con una persona infectada por SARS-CoV-2. El 65% pre sentó infiltrados pulmonares, mayormente con patrón de vidrio esmerilado en la tomografía computarizada de tórax. Casi la mitad de los pacientes tuvo enfermedad grave y crítica, y una alta proporción recibió plasma de convalecientes como tratamiento. Presentaron complicaciones e infecciones hospitalarias el 20% y 15% respec tivamente, y tuvieron una mediana de días de internación prolongada. La mortalidad a 30 días fue del 10%. La infección por SARS-CoV-2 en nuestra población tuvo considerable impacto clínico y epidemiológico.

Abstract. SARS-CoV-2 infection in patients with hematological malignancies and hematopoietic stem cell transplants (HSCT) can be severe and with significant mortality. We carried out a prospective and observational study to describe the clinical and epidemiological characteristics and outcome of SARS-CoV-2 infection in patients with hematological malignancies and HSCT. Twenty adult patients were included with a median age of 58 years and a median Charlson score of 3. Infections were community-acquired and nosocomial in 60% and 40%, respectively, and 30% of the patients had a history of contact with a SARS-CoV-2 infected person. Sixty-five percent had pulmonary infiltrates, mostly with a ground-glass pattern on CT scan. Almost half of the patients had a severe and critical illness, and a high proportion received convalescent plasma as treatment. Twenty percent and 15% had complications and hospital infections, respectively, and had prolonged hospitalization expressed as median days of it. The 30-day mortality was 10%. SARS-CoV-2 infection in our population had a considerable clinical and epidemiological impact.

Humans , Adult , Middle Aged , Hematologic Neoplasms/complications , Hematologic Neoplasms/therapy , COVID-19/therapy , Prospective Studies , Immunization, Passive , SARS-CoV-2
Rev. chil. reumatol ; 37(1): 23-33, 2021. ilus, tab
Article in Spanish | LILACS | ID: biblio-1400380


Introducción: El dolor musculoesquelético (ME) es un motivo de consulta común en la infancia originado en su mayoría por causas banales. Entre las causas menos frecuentes encontramos las patologías reumatológicas y neoplásicas. Se presentan tres casos clínicos que debutaron con artritis o artralgia en los cuales el diagnóstico final fue neoplásico. Casos clínicos: el primer caso fue una Leucemia Linfoblástica Aguda (LLA) de alto riesgo, el segundo caso fue un sarcoma de Ewing y el tercer caso fue una LLA común. Dos de los casos tuvieron evolución desfavorable con fallecimiento. Revisión de la literatura: Se describen hallazgos que deben hacer sospechar una causa neoplásica tales como el dolor ME desproporcionado, alteraciones en el hemograma, velocidad de eritrosedimentación globular y lactato deshidrogenasa elevados, y radiografía con alteraciones sugerentes. Conclusiones: Frente a un dolor ME en el niño se debe tener presente las causas neoplásicas a pesar de su baja frecuencia dado su mal pronóstico.

Introduction: Musculoskeletal (MS) pain is a common complaint in childhood, usually caused by trivial ailments. Among less frequent causes we may find rheumatological and neoplastic pathologies. We present 3 clinical cases in which a rheumatological cause was initially suspected, as they started out with arthritis or arthralgia, but where the diagnosis was finally a neoplasm. Clinical cases: the first case was a high-risk Acute Lymphoblastic Leukemia (ALL), the second case was a Ewing's sarcoma, and the third case was a common ALL. Two of the cases had unfavourable outcomes and passed away. Literature review: Findings that should make us suspect neoplastic causes are disproportionate MS pain, altered hemogram, elevated erythrocyte sedimentation rate and lactate dehydrogenase, and an x ray with suggestive alterations. Conclusions: When faced with MS pain in children, neoplastic causes must be taken into account despite their low frequency given the poor prognosis associated with the diagnosis.

Humans , Male , Child , Musculoskeletal Diseases/etiology , Musculoskeletal Diseases/diagnostic imaging , Hematologic Neoplasms/complications , Radiography , Radionuclide Imaging , Clinical Laboratory Techniques , Diagnosis, Differential , Musculoskeletal Pain/etiology
Med. infant ; 27(2): 192-199, Diciembre 2020.
Article in Spanish | BINACIS, UNISALUD, LILACS | ID: biblio-1151212


Entre los años 2000 y 2016 en Argentina, se reportaron al Registro Oncopediátrico Hospitalario Argentino (ROHA) 22.450 casos de cáncer en niños menores de 15 años de edad. Las Leucemias constituyen la enfermedad oncológica más frecuente, seguida de los Tumores de Sistema Nervioso Central y los Linfomas. Esta distribución es similar a la descripta en los países desarrollados de Europa y Norteamérica. Su tasa de curación a nivel mundial, llega al 80% debido al uso de quimioterapia intensiva, situación que mejora la supervivencia pero que también aumenta la frecuencia de complicaciones. Estas complicaciones pueden ser debidas tanto al propio cáncer como al tratamiento y en ocasiones ser la primera manifestación de la enfermedad oncológica. Los eventos que amenazan la vida en pacientes inmunocomprometidos son mayores que en la población general, y cuando ocurren tienen una mortalidad elevada. El reconocimiento temprano es clave para el resultado en términos de sobrevida y disminución de la mortalidad. Las acciones deberán centrarse al reconocimiento temprano de eventos críticos en pacientes oncológicos. Los pacientes Hemato-Oncológicos constituyen un gran número de ingresos no planificados a las unidades de cuidados intensivos. Uno de cada 4 pacientes requerirá durante su evolución ingreso a Unidades de Cuidados Intensivos. El propósito de este artículo es describir tres de las urgencias oncológicas que requieren con mayor frecuencia admisión en UCI: la presentación y manejo del shock séptico, Shock Cardiogénico y las complicaciones neurológicas en los pacientes con leucemias agudas (AU)

Between 2000 and 2016, 22,450 cases of cancer in children younger than 15 years of age were reported to the Argentine Hospital Registry of Childhood Cancer (ROHA). Leukemia was the most common cancer reported, followed by central nervous system tumors and lymphoma. This distribution is similar to that described in the developed countries of Europe and North America. The worldwide cure rate is up to 80% due to the use of intensive chemotherapy, which improves survival but also increases the complication rate. These complications may be due both to the cancer itself and to the treatment and are sometimes the first manifestation of the disease. Life-threatening events are more common in immunocompromised patients than in the general population, and when they occur, the mortality rate is high. Early recognition is essential for the outcome in terms of survival and decreased mortality. Interventions should focus on early recognition of critical events in cancer patients. Patients with hematology-oncology diseases account for a large number of unplanned admissions to intensive care units (ICU), while one in four of these patients will require admission to the ICU in the course of their disease. The aim of this study was to describe three oncology emergencies that most frequently require ICU admission: septic shock and its management, cardiogenic shock, and neurological complications in patients with acute leukemia (AU)

Humans , Infant , Child, Preschool , Child , Adolescent , Shock, Cardiogenic/etiology , Shock, Cardiogenic/therapy , Shock, Septic/etiology , Shock, Septic/therapy , Intensive Care Units, Pediatric , Leukemia, Myeloid, Acute/complications , Central Nervous System Diseases/etiology , Central Nervous System Diseases/therapy , Hematologic Neoplasms/complications , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Survival Rate , Critical Illness/therapy
J. appl. oral sci ; 28: e20190020, 2020. tab, graf
Article in English | LILACS, BBO | ID: biblio-1056587


Abstract Objective: This study sought to identify the differences between the oral changes presented by patients with solid and hematologic tumors during chemotherapeutic treatment. Methodology: This is an observational, prospective and quantitative study using direct documentation by follow-up of 105 patients from 0 to 18 years using the modified Oral Assessment Guide (OAG). Of the 105 patients analyzed, 57 (54.3%) were boys with 7.3 years (±5.2) mean age. Hematologic neoplasms accounted for 51.4% of all cases. Results: Voice, lips, tongue, and saliva changes were not significantly different (p>0.05) between patients with solid or hematologic tumors and during the follow-up. From the 6th until the 10th week of chemotherapeutic treatment alterations in swallowing function, in the mucous membrane (buccal mucosa and palate), in the labial mucosa, and in the gingiva occurred and were distributed differently between the two tumors groups (p<0.05). The main alterations were observed in patients with hematologic tumors. Conclusion: It was concluded that the oral changes during the chemotherapeutic treatment occurred especially in swallowing function, in the mucous membrane, in the labial mucosa and in the gingiva, and these alterations were found mainly in patients with hematologic tumors.

Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Mouth Diseases/chemically induced , Neoplasms/drug therapy , Antineoplastic Agents/adverse effects , Deglutition Disorders/chemically induced , Prospective Studies , Longitudinal Studies , Hematologic Neoplasms/complications , Hematologic Neoplasms/drug therapy , Mouth Diseases/classification , Mouth Mucosa/pathology , Antineoplastic Agents/therapeutic use
Braz. j. infect. dis ; 23(6): 395-409, Nov.-Dec. 2019. tab, graf
Article in English | LILACS | ID: biblio-1089309


ABSTRACT In the present paper we summarize the suggestions of a multidisciplinary group including experts in pediatric oncology and infectious diseases who reviewed the medical literature to elaborate a consensus document (CD) for the diagnosis and clinical management of invasive fungal diseases (IFDs) in children with hematologic cancer and those who underwent hematopoietic stem-cell transplantation. All major multicenter studies designed to characterize the epidemiology of IFDs in children with cancer, as well as all randomized clinical trials addressing empirical and targeted antifungal therapy were reviewed. In the absence of randomized clinical trials, the best evidence available to support the recommendations were selected. Algorithms for early diagnosis and best clinical management of IFDs are also presented. This document summarizes practical recommendations that will certainly help pediatricians to best treat their patients suffering of invasive fungal diseases.

Humans , Child , Hematologic Neoplasms/microbiology , Invasive Fungal Infections/diagnosis , Invasive Fungal Infections/therapy , Opportunistic Infections , Brazil/epidemiology , Hematopoietic Stem Cell Transplantation , Hematologic Neoplasms/complications , Hematologic Neoplasms/epidemiology , Consensus , Invasive Fungal Infections/etiology , Invasive Fungal Infections/epidemiology
An. bras. dermatol ; 93(1): 133-134, Jan.-Feb. 2018. graf
Article in English | LILACS | ID: biblio-887134


Abstract: Pyoderma gangrenosum may precede, coexist or follow diverse systemic diseases. The bullous variety is usually associated with hematologic disorders. From 31 patients with pyoderma gangrenosum diagnosed in our hospital during 10 years, only 2 presented with the bullous type. One patient had previous diagnosis of chronic myeloid leukemia. Both had fast-progressive, painful lesions, and both showed an excellent response to systemic corticosteroids. In less than 3 months the lesions recurred simultaneously with the progression of chronic myeloid leukemia in one patient and with the initial diagnosis of acute myeloid leukemia in the other one. They died in less than four weeks. These findings emphasize the importance of its timely diagnosis. Cutaneous lesions could be the first predictor of an underlying disease.

Humans , Male , Female , Adult , Aged , Leukemia, Myeloid/complications , Skin Diseases, Vesiculobullous/complications , Pyoderma Gangrenosum/complications , Hematologic Neoplasms/complications , Recurrence , Skin Diseases, Vesiculobullous/pathology , Pyoderma Gangrenosum/pathology , Fatal Outcome
Rev. bras. cancerol ; 64(4): 533-539, 2018.
Article in Portuguese | LILACS | ID: biblio-1025287


Introdução: As neoplasias hematológicas, leucemias e linfomas são patologias que afetam o sangue ou tecidos formadores dele. Durante o período de hospitalização, os pacientes podem desenvolver redução da capacidade funcional que pode interferir na sua função respiratória. Objetivo: Avaliar a influência do tempo de internamento sobre a força muscular respiratória e o nível funcional de adultos com leucemia e linfoma. Método: Estudo observacional, com delineamento longitudinal e abordagem quantitativa, realizado na enfermaria onco-hematológica do Complexo Hospitalar Universitário Professor Edgard Santos (Hupes). A avaliação da força muscular respiratória foi mensurada pelo manovacuômetro e a capacidade funcional pela escala de desempenho de Karnofsky (KPS). Resultados: No decorrer do tempo de internamento dos pacientes, houve uma diminuição da pressão expiratória máxima (PEM) (p=0,000), porém não foi observada diferença significativa na pressão inspiratória máxima (PIM) (p>0,05). Em relação à KPS, os pacientes apresentaram nível de funcionalidade de 70%. Conclusão: Este estudo demonstrou que a PEM foi alterada durante o internamento, porém não houve modificação da PIM e da funcionalidade dos pacientes.

Introduction: Hematologic neoplasms, leukemias and lymphomas are pathologies that affect the blood or tissues that form it. During the hospitalization period patients may develop functional capacity reduction, which may interfere with their respiratory function. Objective: Evaluate the influence of hospitalization time about respiratory muscle strength and functional level of adults with leukemia and lymphoma. Method: Observational study, with longitudinal design and quantitative approach, performed at the onco-hematological ward of the University Hospital Complex Professor Edgard Santos (Hupes). The assessment of respiratory muscle strength was measured using the manovacuometer and functional capacity using the Karnofsky Performance Scale (KPS). Results: During the hospitalization time, there was a decrease in the maximum expiratory pressure (PEM) (p=0.000), but no significant difference was observed in the maximum inspiratory pressure (PIM) (p>0.05). In relation to KPS, the patients presented functional level of 70%. Conclusion: This study demonstrated that PEM was altered during hospitalization, but there was no modification of the PIM and the functionality of the patients.

Introducción: Las neoplasias hematológicas, leucemias y linfomas son patologías que afectan a la sangre o tejidos formadores de él. Durante el período de hospitalización los pacientes pueden desarrollar una reducción de la capacidad functional, que puede interferer en su función respiratoria. Objetivo: Evaluar la influencia del tiempo de internamiento sobre la fuerza muscular respiratoria y nivel funcional de adultos con leucemia y linfoma. Método: Estudio observacional, con delineamiento longitudinal y el enfoque cuantitativo, realizado en la enfermería onco-hematológica del Complejo Hospitalario Universitario Profesor Edgard Santos (Hupes). La evaluación de la fuerza muscular respiratoria se midió utilizando el manovacuómetro y la capacidad funcional utilizando la escala de rendimiento de Karnofsky (KPS). Resultados: En el transcurso del tiempo de internamiento de los pacientes, hubo una disminución de la presión espiratoria máxima (PEM) (p=0,000), pero no se observó diferencia significativa en la presión inspiratoria máxima (PIM) (p>0,05). En relación a KPS, los pacientes presentaron un nivel de funcionalidad del 70%. Conclusión: Este estudio demostró que la PEM fue alterada durante el internamiento, pero no hubo modificación de la PIM y de la funcionalidad de los pacientes.

Humans , Male , Female , Adult , Leukemia/metabolism , Hematologic Neoplasms/complications , Lymphoma/metabolism , Karnofsky Performance Status , Muscle Strength , Length of Stay
Journal of Peking University(Health Sciences) ; (6): 662-665, 2018.
Article in Chinese | WPRIM | ID: wpr-941681


OBJECTIVE@#To analyze the clinical characteristics of patients with hematological tumor or disease before and after reversible posterior leukoen-cephalopathy syndrome (RPLS).@*METHODS@#Five patients were both from Peking University First Hospital Pediatric Hematology-oncology Department in the period from March 2012 to March 2017. The gender, age, BMI, underlying diseases, with or without renal damage, hypertension family history, clinical manifestations of convulsions, hemoglobin, and blood pressure, serum sodium levels before and after convulsion, and other data of the children with RPLS were retrospectively analyzed. In the meantime, we followed up the five patients for 6 months to 66 months, kept a watchful eye on their original condition and the recovery of symptoms and signs of the nervous system. The relevant literature was reviewed.@*RESULTS@#All of the subjects were females in school-age or pre-school age. The underlying diseases were malignant tumor associated with renal involvement or on one side of nephrectomy in 4 of these subjects, while the other one was refractory autoimmune hemolytic anemia. All of the subjects suffered from mild or moderate anemia. The day before RPLS occurred they received chemotherapy made up with cyclophosphamide, vincristine, and actinomycin-D, or the therapy with cyclosporin A and glucocorticoid. The clinical manifestations were afebrile convulsion after getting up in the mooring or in the afternoon. We observed elevation of blood pressure and cutting down of serum sodium compared with themselves. All of the cases recovered soon after management with diazepam, furosemide and amlodipine besylate. Four of them had a good outcomes and did not remain any sequela, while only one girl became childish in emotion and behavior, and then returned gradually to normal two years later. However, by long-term follow-up, the elevation of blood pressure was mainly reviewed in literature.@*CONCLUSION@#The patients attacked by RPLS, with hematology or oncology cases, could have the underlying disease of renal damage and anemia. Blood pressure elevation and serum sodium falling down at the same time may play an important role during the occurrence of RPLS. Remaining stable of blood pressure and electrolyte level together will possibly reduce or mitigate RPLS.

Child , Child, Preschool , Female , Humans , Blood Pressure , Hematologic Neoplasms/complications , Hypertension/etiology , Posterior Leukoencephalopathy Syndrome/therapy , Retrospective Studies , Seizures/etiology
Rev. Assoc. Med. Bras. (1992) ; 63(9): 764-770, 2017. tab
Article in English | LILACS | ID: biblio-896406


Summary Objective: Invasive pulmonary aspergillosis (IPA) is a major challenge in the management of immunocompromised patients. Despite all the advances in diagnosis, it remains a problem. The purpose of our study was to investigate the risk factors associated with IPA seen in patients with hematological malignancies. Method: A total of 152 febrile neutropenia (FEN) patients with hematological malignancies aged over 18 years and receiving high-dose chemotherapy or stem cell transplant between January 1, 2010, and December 31, 2012 were included in the study. Sixty-five (65) cases with IPA according to the European Organization for the Research and Treatment of Cancer and Infectious Diseases Mycoses Study Group criteria were enrolled as the case group, while 87 patients without IPA development during concomitant monitoring were enrolled as the control group. Incidence of IPA was 21.4% (3/14) in patients receiving bone marrow transplant (allogeneic 2, autologous 1) and those cases were also added into the case group. The two groups were compared in terms of demographic, clinical and laboratory findings and risk factors associated with IPA investigated retrospectively. Results: Presence of relapse of primary disease, neutropenia for more than 3 weeks, presence of bacterial infection, and non-administration of antifungal prophylaxis were identified as risk factors associated with IPA. Conclusion: It may be possible to reduce the incidence of the disease by eliminating preventable risk factors. Predicting those risks would, per se, enable early diagnosis and treatment and, thus, the mortality rate of these patients would unquestionably decline.

Humans , Male , Female , Adolescent , Adult , Aged , Young Adult , Opportunistic Infections/immunology , Immunocompromised Host/immunology , Hematologic Neoplasms/complications , Invasive Pulmonary Aspergillosis/etiology , Febrile Neutropenia/complications , Opportunistic Infections/microbiology , Case-Control Studies , Risk Factors , Hematologic Neoplasms/immunology , Invasive Pulmonary Aspergillosis/immunology , Febrile Neutropenia/immunology , Middle Aged
Arq. gastroenterol ; 53(3): 175-179, tab
Article in English | LILACS | ID: lil-787352


ABSTRACT Background Occult hepatitis B infection is characterized by negative hepatitis B surface antigen (HBsAg) and also detectable hepatitis B virus (HBV) -DNA, with or without hepatitis B core antibody (anti-HBc). HBV reactivation in individuals under immunosuppressive therapy is critical, occurring in occult HBV. Objective In this study, we aimed to determine the prevalence of occult HBV infection among hepatitis B surface antigen negative in cancer patients before receiving chemotherapy. Methods Sera from 204 cancer patients who were negative for HBsAg, were tested for anti-HBc antibodies. The samples that were negative for HBsAg but positive for anti-HBc also examined for HBV-DNA by polymerase chain reaction (PCR). Results Of the 204 HBsAg negative blood samples, 11 (5.4%) samples were positive for anti-HBc antibodies. HBV-DNA was detected in 9/11 (81%) of anti-HBc positive samples. Occult HBV infection in hematological cancers was more than solid cancers, 4.8% and 4.3% respectively. There was no significant difference in HBc antibody positivity based on vaccination, previous blood transfusions, history of familial hepatitis or biochemical parameters (ALT, AST, total and direct bilirubin levels) (P>0.05). Conclusion Screening of occult HBV infection by HBsAg, HBV DNA and anti HB core antibody should be suggested as a routine investigation in cancer patients before receiving chemotherapy.

RESUMO Contexto A infecção oculta da hepatite B caracteriza-se por antígeno de superfície da hepatite B (AgHBs) negativo com vírus detectável da hepatite B (HBV) -DNA, com ou sem anticorpo de núcleo da hepatite B (anti-HBc). A reativação do HBV em indivíduos sob terapia imunossupressora é crítica, originando a infecção oculta pelo VHB. Objetivo Este estudo teve como objetivo determinar a prevalência de infecção oculta pelo VHB entre em pacientes com câncer e com antígeno de superfície da hepatite B negativo antes de receber quimioterapia. Métodos Soro de 204 pacientes com câncer que foram negativos para AgHBs, foram testados para anticorpos anti-HBc. As amostras que foram negativos para AgHBs, mas positivo para anti-HBc foram também examinadas para HBV-DNA, por reação em cadeia da polimerase. Resultados Entre 204 amostras de sangue AgHBs negativas, 11 (5,4%) foram positivos para anticorpos anti-HBc. HBV-DNA foi detectado em 9/11 (81%) das amostras positivas de anti-HBc. Infecção oculta de VHB em câncer hematológico foi maior que em cânceres sólidos, 4,8% e 4,3% respectivamente. Não houve diferença significativa na positividade anti-HBc, com base na vacinação, transfusões de sangue anteriores, história de hepatite familiar ou parâmetros bioquímicos (ALT, AST, total e níveis de bilirrubina total) (P & gt; 0,05). Conclusão A triagem de infecção oculta por AgHBs, HBV-DNA e anti-anticorpo de núcleo HB deve ser sugerida como uma investigação de rotina em pacientes com câncer antes de receber a quimioterapia.

Humans , Male , Female , Adult , Aged , Aged, 80 and over , DNA, Viral/isolation & purification , Hepatitis B virus/isolation & purification , Hepatitis B/epidemiology , Hepatitis B Surface Antigens/blood , Neoplasms/complications , Neoplasms/immunology , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Prevalence , Cross-Sectional Studies , Hematologic Neoplasms/complications , Hematologic Neoplasms/immunology , Hematologic Neoplasms/epidemiology , Hepatitis B/complications , Hepatitis B/diagnosis , Hepatitis B Antibodies/blood , Hepatitis B Surface Antigens/immunology , Iran/epidemiology , Middle Aged
Rev. méd. Chile ; 144(7): 894-899, jul. 2016. tab
Article in Spanish | LILACS | ID: lil-794003


Background: Fatigue is one of the most common and distressing symptoms experienced by cancer patients. Aim: To validate the Brief Fatigue Inventory in people treated for hematological neoplasms. Material and Methods: In a cross-sectional study, the Brief Fatigue Inventory was answered by 122 patients aged 40 ± 14 years (50% women) treated for hematological neoplasms at an intensive hematological unit of a public hospital between July 2010 and July 2013. Socio-demographic and clinical parameters were obtained from their clinical records. Results: Fatigue was present in nearly all patients (99.2%) in minor (50%), moderate (36.9%) or severe (12.3%) levels. The average fatigue score was 4.5 ± 1.9). The Brief Fatigue Inventory had a good internal consistency (Cronbach’s alpha = 0.973) and proved to be one-dimensional (84.3% of the explained variance). Women reported that fatigue interfered more with enjoy­ment of life than men (p = 0.036). Conclusions: The Brief Fatigue Inventory is a reliable instrument that can be used in clinical practice. It allows a quick assessment of the level of fatigue. People treated for hematologic cancer have a high prevalence of fatigue.

Humans , Male , Female , Adolescent , Adult , Middle Aged , Young Adult , Hematologic Neoplasms/complications , Fatigue/diagnosis , Fatigue/etiology , Cross-Sectional Studies , Risk Assessment
Rio de Janeiro; s.n; 2016. 58 f p. tab.
Thesis in Portuguese | LILACS | ID: biblio-987282


O transplante de células tronco hematopoiéticas (TCTH) é uma modalidade de tratamento oncológico associada a consideráveis níveis de morbidade. Num cenário onde pacientes sobrevivem por períodos mais longos de tempo, tem sido dada atenção às sequelas tardias deste procedimento. A presente revisão sistemática pretende compilar as informações publicadas acerca da prevalência de transtornos mentais entre os sobreviventes ao TCTH para tratamento das neoplasias hematológicas e linfoides na infância e na adolescência, bem como os possíveis fatores associados à ocorrência desses transtornos. Foram utilizadas 13 bases de dados para pesquisar publicações desde 1990 até janeiro de 2016. Após aplicação de critérios de inclusão e exclusão, foram selecionados oito artigos para revisão. Foram estudados 8449 indivíduos, dentre os quais 1009 sobreviventes ao TCTH. A idade média ao diagnóstico variou de 5 a 9 anos e os indivíduos foram avaliados de 1 a 16 anos após o diagnóstico. Os desfechos em saúde mental estudados foram os domínios psicológicos e mentais das escalas de qualidade de vida (QV), depressão, distúrbios de conduta, auto estima, e transtornos hipercinéticos, do comportamento, do funcionamento social, da alimentação e do sono, sendo utilizados nove instrumentos diferentes para avaliação. Dentre os resultados encontrados, observa-se que os desfechos tendem a ser mais desfavoráveis quando os pais são os respondentes dos questionários em comparação com aqueles em que os próprios pacientes os respondem. Os resultados também tendem a ser piores quando os pacientes já são adultos, quando em comparação com a avaliação realizada ainda na infância ou adolescência, e menos favoráveis quando a população de transplantados é comparada com a população geral, com diferenças menos significativas quando esta comparação se faz com pacientes não transplantados. Os efeitos físicos tardios, a intensidade do tratamento sobre o Sistema Nervoso Central (SCN) e a depressão materna foram reconhecidos como possíveis variáveis explicativas para alterações na saúde mental dos sobreviventes. Quanto à qualidade dos artigos, a maioria recebeu menos de dois terços da pontuação máxima da Newcastle - Ottawa Quality Assessment Scale. O presente estudo apresenta limitações impostas pelo número escasso de artigos e pelas diferenças metodológicas dos estudos sobre o tema. A heterogeneidade dos estudos não permitiu a realização de metanálise. Contudo, esta revisão apresenta-se como a primeira a agrupar o conhecimento até então publicado sobre a saúde mental dos sobreviventes ao TCTH na infância e adolescência como parte do tratamento para as neoplasias hematológicas e linfoides. Seus resultados levam ao reconhecimento da importância deste tema, bem como às lacunas que ainda se apresentam. Sendo tais neoplasias as mais frequentes entre crianças e adolescentes, com taxas cada vez mais altas de sobrevivência, há que se pensar sobre a possível subnotificação destas consequências. O rastreamento das sequelas mentais no seguimento a longo prazo dessa população poderia trazer à tona um retrato mais fidedigno das repercussões mentais, que tanto a doença quanto seu agressivo tratamento com TCTH podem gerar

Hematopoietic stem cell transplantation (HSCT) is a modality of oncological treatment associated with considerable levels of morbidity. In a setting where patients survive for longer periods of time, attention has been paid to the late sequelae of this procedure. The present systematic review aims to compile the published information on the prevalence of mental disorders among survivors of HSCT for the treatment of hematological and lymphoid neoplasms in childhood and adolescence, as well as the possible factors associated with the occurrence of these disorders. We used 13 databases to search publications from 1990 to January 2016. After applying inclusion and exclusion criteria, eight articles were selected for review. A total of 8449 individuals were studied, including 1009 survivors of HSCT. The mean age at diagnosis ranged from 5 to 9 years and subjects were assessed from 1 to 16 years after diagnosis. The mental health outcomes studied were the psychological and mental domains of quality of life (QoL), depression, behavioral disorders, self-esteem, and hyperkinetic disorders, behavior, social functioning, eating and sleep, being used nine different instruments for evaluation. Among the results found, it is observed that the outcomes tend to be more unfavorable when the parents are the respondents of the questionnaires compared to those in which the patients themselves respond. The results also tend to be worse when patients are already adults, when compared to the evaluation performed in childhood or adolescence, and less favorable when the transplant population is compared to the general population, with less significant differences when this comparison with non-transplanted patients. Late physical effects, intensity of treatment on the Central Nervous System (CNS) and maternal depression were recognized as possible explanatory variables for changes in the mental health of survivors. As for the quality of the articles, the majority received less than two thirds of the Newcastle - Ottawa Quality Assessment Scale. The present study presents limitations imposed by the scarce number of articles and the methodological differences of the studies on the subject. The heterogeneity of the studies did not allow meta-analysis. However, this review is the first to group previously published knowledge on the mental health of survivors of HSCT in childhood and adolescence as part of the treatment for hematological and lymphoid neoplasms. Its results lead to the recognition of the importance of this theme, as well as to the gaps that still exist. As these neoplasms are the most frequent among children and adolescents, with increasing rates of survival, it is necessary to think about the possible underreporting of these consequences. The tracking of mental sequelae in the long-term follow-up of this population could bring to the surface a more reliable picture of the mental repercussions that both the disease and its aggressive treatment with HSCT can generate

Humans , Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Survival/psychology , Review Literature as Topic , Child , Mental Health , Morbidity , Adolescent , Hematopoietic Stem Cell Transplantation/adverse effects , Hematologic Neoplasms/complications
Indian J Cancer ; 2014 Apr-Jun; 51(2): 180-183
Article in English | IMSEAR | ID: sea-154333


BACKGROUND: Patients with hematological malignancies that are highly proliferative and have high tumor burden are at high risk of developing hyperuricemia and tumor lysis syndrome (TLS), spontaneously and while undergoing chemotherapy. AIM: To assess the safety and efficacy of a new generic formulation of recombinant rasburicase in prevention and treatment of malignancy‑associated hyperuricemia. MATERIALS AND METHODS: An open‑label, multicenter, phase‑III study was conducted on 100 eligible patients with high risk for TLS. Rasburicase was administered 0.2 mg/kg intravenously over 30 min, daily, for 4 days. The outcome measures were percentage of reduction in plasma uric acid at 4 h after rasburicase, plasma uric acid area under the curve (AUC)0-96 h and incidence of adverse events. RESULTS: Eighty eight patients completed the study period of 10 days. After rasburicase administration, there was a 75.3 ± 28.5% of reduction in plasma uric acid at 4 h as compared to baseline. The plasma uric acid AUC0-96 h was 259.9 ± 215.5 mg/dL h. Safety of rasburicase was assessed on the basis of changes in vitals, hematological, and biochemical parameters from baseline to termination. Except for the plasma uric acid level, there was no significant difference in any of the parameters. Mild to moderate adverse events were reported in 29 patients. Three patients had serious adverse events (SAEs) unrelated to rasburicase. CONCLUSIONS: These results demonstrated that recombinant rasburicase that is indigenously developed is effective for prevention and management of hyperuricemia in patients who are at high risk of developing TLS.

Adult , Aged , Area Under Curve , Child , Female , Gout Suppressants/therapeutic use , Hematologic Neoplasms/complications , Humans , Hyperuricemia/drug therapy , Hyperuricemia/etiology , India , Male , Middle Aged , ROC Curve , Tumor Lysis Syndrome/prevention & control , Urate Oxidase/therapeutic use , Uric Acid/blood , Young Adult
Hematology, Oncology and Stem Cell Therapy. 2014; 7 (4): 127-135
in English | IMEMR | ID: emr-153846


Pulmonary alveolar proteinosis [PAP], characterized by deposition of intra-alveolar PAS positive protein and lipid rich material, is a rare cause of progressive respiratory failure first described by Rosen et al. in 1958. The intra-alveolar lipoproteinaceous material was subsequently proven to have been derived from pulmonary surfactant in 1980 by Singh et al. Levinson et al. also reported in 1958 the case of 19-year-old female with panmyelosis afflicted with a diffuse pulmonary disease characterized by filling of the alveoli with amorphous material described as "intra-alveolar coagulum". This is probably the first reported case of PAP in relation to hematologic malignancy. Much progress has been made on PAP first described by Rosen which is currently classified as idiopathic or primary or autoimmune PAP. Idiopathic PAP occurs as a result of auto-antibodies directed against granulocyte-macrophage colony stimulating factor [GM-CSF] impeding the surfactant clearing function of alveolar macrophages leading to progressive respiratory failure. Whole lung lavage and GM-CSF therapy has improved outcomes in patients with idiopathic PAP. Despite major advancement in the management of hematologic malignancy and its complications, little is known about the type of PAP first described by Levinson and now known as secondary PAP; a term also used when PAP occurs due to other causes such as occupational dusts. In this article we review and analyze the limited literature available in secondary PAP due to hematologic malignancies and present a case of PAP associated with chronic lymphocytic leukemia successfully treated with bendamustine and rituximab

Humans , Male , Hematologic Neoplasms/complications , Pulmonary Alveolar Proteinosis/therapy , Bronchoalveolar Lavage , Opportunistic Infections , Hematopoietic Stem Cell Transplantation , Hematologic Neoplasms/diagnosis
Clin. biomed. res ; 34(2): 169-174, 2014. tab
Article in Portuguese | LILACS | ID: biblio-997739


INTRODUÇÃO: A neutropenia febril é uma complicação frequente dos pacientes submetidos ao tratamento quimioterápico ou Transplante de Célula Tronco Hematopoiética (TCTH). A fibrobroncoscopia (FBC) flexível tem sido utilizada para auxiliar no diagnóstico de doenças pulmonares. No entanto, não há consenso em relação ao benefício do exame para estabelecer diagnóstico e alterar o tratamento das doenças pulmonares nesse contexto. Estudos prévios, retrospectivos e bastante heterogêneos, com pacientes imunocomprometidos não-HIV mostraram que o rendimento da fibrobroncoscopia para estabelecer diagnóstico etiológico varia de 13 a 81% e gera alteração de terapêutica em 5 e 51%. O objetivo deste estudo foi avaliar o rendimento da Fibrobroncoscopia, o risco ao procedimento em pacientes hematológicos e neutropênicos. MÉTODOS: Estudo transversal retrospectivo que avaliou pacientes com neoplasia hematológica e neutropenia febril e que tenham sido submetidos à fibrobroncoscopia diagnóstica entre janeiro de 2011 e dezembro de 2012 internados no Hospital de Clínicas de Porto Alegre. RESULTADOS: Foram incluídos 45 pacientes: 18 (36%) tiveram resultado positivo no Lavado Broncoalveolar (LAB), sendo que houve mudança na conduta terapêutica em 95% dos pacientes que apresentaram positividade no LAB. Com relação ao risco do procedimento tivemos uma taxa de 2,2% de complicação, com um paciente que apresentou dessaturação imediatamente após o procedimento. CONCLUSÃO: Apesar do número limitado de pacientes, nossos achados indicam que a realização da fibrobroncoscopia com LAB em pacientes neutropênicos é segura e com um rendimento semelhante aos descritos na literatura

INTRODUCTION: Febrile neutropenia is a common complication in patients undergoing chemotherapy or hematopoietic Stem Cell Transplantation (HSCT). Flexible fiberoptic bronchoscopy has been used to aid in the diagnosis of pulmonary diseases. However, there is no consensus regarding the benefit of the exam in establishing diagnosis and in changing the treatment of lung disease in this context. Previous retrospective studies, quite heterogeneous and with non-HIV immunocompromised patients, showed that the yield of fiberoptic bronchoscopy in establishing etiology ranges from 13% to 81%, and in changing therapy, from 5% to 51%. To evaluate the efficiency of Fiberoptic bronchoscopy and the procedure-related risk for neutropenic patients with hematologic malignancy. METHODS: This retrospective cross-sectional study analyzed the medical records of patients with hematologic malignancy with febrile neutropenia who had undergone diagnostic fiberoptic bronchoscopy between January 2011 and December 2012 at the Hospital de Clínicas de Porto Alegre. RESULTS: A total of 45 patients were included: 18 (36%) tested positive for bronchoalveolar lavage, with change in therapeutic management occurring for 95% of them. The procedure-related risk was 2.2%, with one patient showing desaturation immediately after the procedure. CONCLUSION: Despite the limited number of patients, our findings indicate that fiberoptic bronchoscopy in neutropenic patients is safe, and the results are similar to those previously reported

Humans , Male , Adult , Respiratory Tract Infections/etiology , Bronchoscopy , Bronchoalveolar Lavage , Febrile Neutropenia/complications , Hematopoietic Stem Cell Transplantation/adverse effects , Hematologic Neoplasms/complications